About half of the CRC patients have activating mutations in RAS which lead to continuous activation of phosphoinositide 3 kinase (PI3K)/Akt/mechanistic target of rapamycin complex 1 (mTORC1) pathway [83]. Here, PIK3CA is linked to colorectal carcinoma.